chartexchange

Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher

ETF Trends | Nov 4, 2026 2:44 PM EST

The Amplify Weight Loss Drug & Treatment ETF (THNR) returned 3.2% in October, according to Amplify ETFs. Eli Lilly and Co. (LLY) drove most of that gain, after reporting quarterly results that beat Wall Street forecasts. Key Takeaways: Regeneron, Roche and AstraZeneca each climbed more than 15% during October in THNR’s underlying index. Eli Lilly [...]
The post Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher appeared first on ETF Trends .

Read original article